Caisse de depot et placement du Quebec bought a new stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 492,139 shares of the life sciences company’s stock, valued at approximately $86,533,000. Caisse de depot et placement du Quebec owned approximately 0.33% of Illumina as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also modified their holdings of the stock. Elyxium Wealth LLC acquired a new position in Illumina in the 4th quarter worth $25,000. Laurel Wealth Advisors LLC purchased a new position in Illumina in the 4th quarter valued at about $26,000. Fiduciary Financial Advisors acquired a new stake in shares of Illumina during the second quarter valued at about $26,000. Quarry LP acquired a new stake in shares of Illumina during the third quarter valued at about $32,000. Finally, Activest Wealth Management increased its position in shares of Illumina by 671.9% during the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 215 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,034,688 shares of company stock valued at $417,970,281 in the last 90 days. Insiders own 2.90% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on Illumina
Illumina Stock Performance
Illumina stock opened at $227.69 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $231.81. The company has a fifty day moving average price of $192.98 and a two-hundred day moving average price of $155.18. The company has a market cap of $34.38 billion, a PE ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45.
Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Read More
- Five stocks we like better than Illumina
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
